News
FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 20274FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback